Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 15/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | WNT1 | P04628 | 2/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | CLK3 | P49761 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20075391 | 0.89 | GSK3B (0.51) | GSK3BDYRK1AWNT1CLK2CLK3 | |
| SCHEMBL20074608 | 0.88 | CNR1 (0.43) | GSK3BDYRK1ACNR1HSD11B1 | |
| SCHEMBL20075350 | 0.87 | P2RY14 (0.47) | GSK3BDYRK1AWNT1CLK2CLK3 | |
| SCHEMBL20074641 | 0.86 | CNR1 (0.42) | GSK3BDYRK1ACNR1HSD11B1 | |
| SCHEMBL20074710 | 0.86 | GSK3B (0.43) | GSK3BDYRK1ACNR1CLK2CLK3 | |
| SCHEMBL18496602 | 0.81 | SCN10A (0.46) | CNR1HSD11B1 | |
| SCHEMBL19641950 | 0.81 | CNR1 (0.47) | CNR1HSD11B1 | |
| SCHEMBL18706164 | 0.79 | CNR1 (0.43) | CNR1HSD11B1 | |
| SCHEMBL18496661 | 0.78 | DYRK1A (0.52) | DYRK1ACNR1 | |
| SCHEMBL19641917 | 0.77 | CNR1 (0.44) | CNR1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563049-B | Imidazole compounds as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2022-11-29 | — | — | CN | claimed |
| EP-3526201-B1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-11-18 | — | — | EP | claimed |
| CN-109563049-B | Imidazole compounds as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2022-11-29 | — | — | CN | disclosed |
| EP-3526201-B1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-11-18 | — | — | EP | disclosed |
| EP-3526201-B1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-11-18 | — | — | EP | disclosed |
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190233379-A1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20190233379-A1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-08-01 | — | — | US | disclosed |
| WO-2018069362-A1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | SLC1A1, SLC1A3, SLC1A2 | GSK3B 2961/4885DYRK1A 3045/4885CNR1 2639/4885 |
| US-20190233379-A1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | SLC1A1, SLC1A3, SLC1A2 | GSK3B 2961/4885DYRK1A 3045/4885CNR1 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.